SNN – Smith & Nephew plc
Float Short %
0.6
Margin Of Safety %
23
Put/Call OI Ratio
0.32
EPS Next Q Diff
EPS Last/This Y
0.63
EPS This/Next Y
0.21
Price
36.77
Target Price
38.03
Analyst Recom
2.33
Performance Q
3.64
Relative Volume
0.69
Beta
0.7
Ticker: SNN
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-10-06 | SNN | 35.9 | 0.22 | 0.00 | 257 |
| 2025-10-07 | SNN | 35.76 | 0.22 | 0.00 | 253 |
| 2025-10-08 | SNN | 35.92 | 0.22 | 0.00 | 253 |
| 2025-10-09 | SNN | 35.73 | 0.23 | 0.00 | 246 |
| 2025-10-10 | SNN | 35.1 | 0.23 | 0.00 | 246 |
| 2025-10-13 | SNN | 35.21 | 0.23 | 0.00 | 246 |
| 2025-10-14 | SNN | 35.26 | 0.23 | 0.00 | 246 |
| 2025-10-15 | SNN | 35.36 | 0.23 | 0.00 | 246 |
| 2025-10-16 | SNN | 35.81 | 0.23 | 0.00 | 246 |
| 2025-10-17 | SNN | 36.33 | N/A | N/A | 0 |
| 2025-10-20 | SNN | 36.33 | N/A | N/A | 0 |
| 2025-10-21 | SNN | 36.56 | 0.23 | 0.00 | 243 |
| 2025-10-22 | SNN | 37.15 | 0.20 | 0.02 | 275 |
| 2025-10-23 | SNN | 36.49 | 0.20 | 0.02 | 275 |
| 2025-10-24 | SNN | 36.59 | 0.20 | 0.02 | 275 |
| 2025-10-27 | SNN | 36.67 | 0.20 | 0.02 | 275 |
| 2025-10-28 | SNN | 36.56 | 0.17 | 999.99 | 317 |
| 2025-10-29 | SNN | 35.78 | 0.32 | 1.00 | 357 |
| 2025-10-30 | SNN | 35.79 | 0.32 | 1.00 | 357 |
| 2025-10-31 | SNN | 36.8 | 0.32 | 1.00 | 357 |
| 2025-11-03 | SNN | 36.78 | 0.32 | 6.00 | 359 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-10-06 | SNN | 35.91 | - | 264.4 | 1.86 |
| 2025-10-07 | SNN | 35.76 | - | 274.7 | 1.86 |
| 2025-10-08 | SNN | 35.92 | - | 284.1 | 1.86 |
| 2025-10-09 | SNN | 35.74 | - | 274.7 | 1.86 |
| 2025-10-10 | SNN | 35.08 | - | 258.4 | 1.86 |
| 2025-10-13 | SNN | 35.22 | - | 282.0 | 1.86 |
| 2025-10-14 | SNN | 35.26 | - | 280.1 | 1.86 |
| 2025-10-15 | SNN | 35.35 | - | 292.7 | 1.86 |
| 2025-10-16 | SNN | 35.81 | - | 297.7 | 1.57 |
| 2025-10-17 | SNN | 36.34 | - | 292.6 | 1.57 |
| 2025-10-20 | SNN | 36.33 | - | 285.6 | 1.57 |
| 2025-10-21 | SNN | 36.56 | - | 286.3 | 1.57 |
| 2025-10-22 | SNN | 37.17 | - | 295.0 | 1.57 |
| 2025-10-23 | SNN | 36.49 | - | 263.1 | 1.57 |
| 2025-10-24 | SNN | 36.57 | - | 277.7 | 1.57 |
| 2025-10-27 | SNN | 36.67 | - | 280.2 | 1.57 |
| 2025-10-28 | SNN | 36.54 | - | 278.3 | 1.57 |
| 2025-10-29 | SNN | 35.77 | - | 260.5 | 1.57 |
| 2025-10-30 | SNN | 35.77 | - | 258.3 | 1.57 |
| 2025-10-31 | SNN | 36.82 | - | 294.7 | 1.57 |
| 2025-11-03 | SNN | 36.77 | - | 300.0 | 1.57 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-10-06 | SNN | 0.00 | 2.55 | 0.56 |
| 2025-10-07 | SNN | 0.00 | 2.55 | 0.56 |
| 2025-10-08 | SNN | 0.00 | 2.55 | 0.56 |
| 2025-10-09 | SNN | 0.00 | 2.55 | 0.56 |
| 2025-10-10 | SNN | 0.00 | 2.55 | 0.60 |
| 2025-10-13 | SNN | 0.00 | 2.53 | 0.60 |
| 2025-10-14 | SNN | 0.00 | 2.53 | 0.60 |
| 2025-10-16 | SNN | 0.00 | 2.53 | 0.60 |
| 2025-10-17 | SNN | 0.00 | 2.53 | 0.60 |
| 2025-10-20 | SNN | 0.00 | -3.88 | 0.60 |
| 2025-10-21 | SNN | 0.00 | -3.88 | 0.60 |
| 2025-10-22 | SNN | 0.00 | -3.88 | 0.60 |
| 2025-10-23 | SNN | 0.00 | -3.88 | 0.60 |
| 2025-10-24 | SNN | 0.00 | -3.88 | 0.60 |
| 2025-10-27 | SNN | 0.00 | -3.09 | 0.60 |
| 2025-10-28 | SNN | 0.00 | -3.09 | 0.60 |
| 2025-10-29 | SNN | 0.00 | -3.09 | 0.60 |
| 2025-10-30 | SNN | 0.00 | -3.09 | 0.60 |
| 2025-10-31 | SNN | 0.00 | -3.09 | 0.60 |
| 2025-11-03 | SNN | 0.00 | -4.78 | 0.60 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
Avg. EPS Est. Next Quarter
Insider Transactions
Institutional Transactions
-4.78
Beta
0.7
Average Sales Estimate Current Quarter
1508
Average Sales Estimate Next Quarter
1669
Fair Value
45.22
Quality Score
81
Growth Score
87
Sentiment Score
98
Actual DrawDown %
20.2
Max Drawdown 5-Year %
-50.5
Target Price
38.03
P/E
32.77
Forward P/E
16.05
PEG
2.28
P/S
2.61
P/B
2.9
P/Free Cash Flow
19.49
EPS
1.12
Average EPS Est. Cur. Y
1.57
EPS Next Y. (Est.)
1.78
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
8.27
Relative Volume
0.69
Return on Equity vs Sector %
-16.9
Return on Equity vs Industry %
-9.6
EPS 1 7Days Diff
-0.3
EPS 1 30Days Diff
-0.29
EBIT Estimation
300
Smith & Nephew SNATS, Inc.Sector: Healthcare
Industry: Medical Devices
Employees: 17000
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. It operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
stock quote shares SNN – Smith & Nephew plc Stock Price stock today
news today SNN – Smith & Nephew plc stock forecast ,stock prediction 2023 2024 2025
marketwatch SNN – Smith & Nephew plc yahoo finance google finance
stock history SNN – Smith & Nephew plc invest stock market
stock prices SNN premarket after hours
ticker SNN fair value insiders trading